Department of Error (DOI:10.1016/S0140-6736(07)60004-X);Questions about adjuvant trastuzumab still remain

Lancet

Volumn 369, Issue 9555, 2007, Pages 3-5

  Hind, Daniel ^a   Pilgrim, Hazel ^a   Ward, Sue ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; DISEASE FREE SURVIVAL; DRUG COST; DRUG FATALITY; DRUG SAFETY; FUNDING; HEART DISEASE; HUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT RESPONSE;

EID: 33845874369     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)60311-0     Document Type: Erratum

References (17)

1. Smith I., Procter M., Gelber R., and for the HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369 (2007) 29-36
2. Piccart-Gebhart M., Procter M., Leyland-Jones B., and for the Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 (2005) 1659-1672
3. Romond E., Perez E., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 (2005) 1673-1684
4. Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. 28th San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, Dec 8-11, 2005: 1 (abstr).
5. Joensuu H., Kellokumpu-Lehtinen P., Bono P., et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354 (2006) 809-820
6. Ward S., Pilgrim H., and Hind D. Trastuzumab for the treatment of primary breast cancer in HER2 positive women: a single technology appraisal (May, 2006). http://www.nice.org.uk/download.aspx?o=328487 (accessed Oct 24, 2006)
7. Ewer M., Vooletich M., Durand J., et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 23 (2005) 7820-7826
8. Steinherz L., Steinherz P., Tan C., Heller G., and Murphy M. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266 (1991) 1672-1677
9. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemo-therapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
10. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal (reference N0515) (May 7, 2004). http://www.nice.org.uk/page.aspx?o=201974 (accessed Oct 18, 2006)
11. Barrett A., Roques T., Small M., and Smith R. How much will Herceptin really cost?. BMJ 333 (2006) 1118-1120
12. National Institute for Health and Clinical Excellence. 2006/042 NICE welcomes new initiative to help NHS reduce spending on treatments that do not improve patient care (Sept 6, 2006). http://www.nice.org.uk/page.aspx?o=360944 (accessed Oct 18, 2006)
13. Rawlins M., and Dillon A. NICE discrimination. J Med Ethics 31 (2005) 683-684
14. PHARMAC. Herceptin status unchanged following further PTAC advice (Oct 16, 2006). http://www.pharmac.govt.nz/pdf/161006.pdf (accessed Oct 20 2006)
15. SABCS. Trastuzumab in combination therapy for HER2-positive early breast cancer patients. San Antonio Breast Cancer Symposium Newsletter 2 (2005) 2-3
16. National Institute for Health and Clinical Excellence. Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer (August, 2006). http://www.nice.org.uk/download.aspx?o=TA107guidance (accessed Oct 20 2006)
17. Annotated draft labeling text: anotated redlined draft package insert. Herceptin® trastuzumab. Warnings: cardiomyopathy. US Genentech, Inc. (November, 2006). http://www.fda.gov/cder/foi/label/2006/103792s5150lbl.pdf (accessed Nov 24. 2006)